This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)

This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

Clinical Trial Results for Eczema (Atopic Dermatitis - Pediatric)

Focus your search

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Description

Conditions

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Description

Conditions